MaaT Pharma SA (EPA:MAAT)

Market Cap	79.46M
Revenue (ttm)	3.22M
Net Income (ttm)	-28.90M
Shares Out	16.08M
EPS (ttm)	-2.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,391
Average Volume	8,663
Open	4.980
Previous Close	4.940
Day's Range	4.750 - 5.040
52-Week Range	4.700 - 9.960
Beta	0.06
RSI	43.00
Earnings Date	Sep 16, 2025

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 67
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.